Medtronic Begins CoreValve™ Evolut™ R "Real World" TAVR Study

Medtronic plc (NYSE: MDT) has announced the start of a new "real world" study of its CoreValve Evolut R transcatheter aortic valve. The first patients were enrolled at University Hospital in Bonn, Germany. The FORWARD study will enroll up to 1,000 patients at 60 centers worldwide.
Source: News from Angioplasty.Org - Category: Cardiology Source Type: news